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Purpose: To evaluate the effect of orbital steroid injections in patients with active thyroid
ophthalmopathy resistant to or dependent on systemic steroids, or with complications
related to systemic steroid use.
Methods: This prospective non-comparative case series includes 31 eyes of 17 patients
with active thyroid ophthalmopathy and clinical activity score (CAS) of 3 or more,
without compressive optic neuropathy or overt exposure keratopathy. All subjects had
a history of previous systemic steroid use (with steroid resistance or dependence) or
had developed complications related to steroids. A combination of steroids including
triamcinolone acetonide 20mg and dexamethasone 4mgwas injected in the upper and
lower retroseptal orbital spaces three or four times at one-month intervals. The patients
were examined periodically after each injection and at least three months after the last
injection.
Results: Mean pre-injection CAS was 5.2 ± 1.3 which was improved to 1.6 ± 1 after
the fourth injection (P < 0.001). Upper and lower lid retraction improved in 100% and
68.2% of the affected eyes, respectively. Strabismus completely resolved in one of five
affected patients and the most significant improvement was observed in supraduction.
Mean improvement in exophthalmos was 1.2 ± 1.1 mm. Visual acuity did not significantly
change after the injections. Eyelid ecchymosis and/or subconjunctival hemorrhage was
observed in 7.1% and intraocular pressure rise occurred in 8.8% of eyes.
Conclusion: Orbital steroid injections can be used for the treatment of active thyroid
ophthalmopathy when the patient is resistant to or dependent on systemic steroids or
has developed complications of systemic steroids.
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INTRODUCTION
Graves’ disease is a common autoimmune dis-
order associated with thyroid dysfunction which
presents with various metabolic and immunologic
disturbances.[1–4]
Orbital tissues become involved in up to 50%
of patients with Graves’ disease. Because of the
compact arrangement of tissues in the confined
space of the orbit, variable degrees of inflam-
mation can lead to serious complications such
as proptosis, strabismus, corneal exposure, and
compressive optic neuropathy. Drastic signs are
fortunately uncommon and are observed in less
than 5% of Graves’ patients.[1–4] Ophthalmopathy in
Graves’ disease often lasts for one–two years and
the peak of disease activity precedes the peak of
disease severity by six months.[4]
In mild forms of Graves’ ophthalmopathy, con-
servative management such as the use of lubri-
cants, administration of oral selenium, control of
thyroid dysfunction, and cessation of smoking may
suffice;[3, 5] however, moderate to severe cases
may require systemic steroids via oral or intra-
venous routes.[6, 7]
Due to resistance to and dependence on
steroids, or complications related to systemic use
of steroids including gastric ulcer, osteoporosis,
activation of tuberculosis, weight gain, increased
glucose levels, and systemic hypertension,[8]
some authors have suggested local injection of
steroids.[9–20] Steroids may be injected locally in
the subconjunctival space[9–12] or retroseptally
within the orbital space,[13–19] and have been
shown to entail lower complications than systemic
steroids.[20]
Herein, the authors present the results of intraor-
bital injection of steroids in patients with active
Graves’ ophthalmopathy resistant to or dependent
on steroids or subjects who had developed serious
complications due to systemic steroids.
METHODS
This prospective interventional case series was
approved by the Scientific and Ethics Commit-
tee of the Ophthalmic Research Center at the
Shahid Beheshti University of Medical Sciences
and adhered to the principles outlined in The Dec-
laration of Helsinki and written informed consent
was taken from all the patients.
In the current series, we included adult sub-
jects from January 2017 to March 2018, affected
by thyroid ophthalmopathy with disease activ-
ity and severity score of 3 or more who had
received oral or intravenous steroids. All patients
were resistant to, or dependent on, steroids or
had developed systemic complications such as
hyperglycemia, hypertension, gastric ulcer, major
depression, unacceptable weight gain or moon
face, and the patient was unwilling to continue
systemic steroids.
The exclusion criteria consisted of compres-
sive optic neuropathy, glaucoma, active periocular
infections, history of orbital radiation and antico-
agulation therapy. All patients were instructed to
discontinue systemic steroids at least four weeks
before consideration for the new treatment modal-
ity. Any patient who failed to adhere to the treat-
ment schedule up to the end of the study period
was also excluded.
After obtaining a complete history related to
the disease, a comprehensive eye examination
was performed including slit lamp examination,
funduscopy, and tonometry. External examination
included evaluation of eyelid condition and severity
of lid retraction. Ocular deviation was assessed
using prisms to compensate for any diplopia.
Limitations in eye movements were documented
as duction limitations. Exophthalmometry was per-
formed employing the Naugle exophthalmometer.
To evaluate the activity and severity of Graves’
disease, we used the “Clinical Activity Score”
(CAS) that includes 10 grades and the “NOSPECS”
method that consists of 6 grades, respectively.[21–24]
All intraorbital injections were performed by the
first author (AB) in the operation room under stand-
by anesthesia with systemicmonitoring by an anes-
thesiologist. After sterilization of both lids with ethyl
alcohol 90%, triamcinolone acetonide 20 mg (Exir,
Iran) plus dexamethasone 4 mg (Darou Pakhsh,
Iran) were prepared in a 2 ml syringe for each
injection site and were injected into both superior
and inferior retroseptal orbital space from the
middle of the orbital rim using a #26 gauge needle
2.5 inches in length while the globe was protected
by the free hand of the surgeon. The volume of
injection for each site was 1 ml and a total of 2 ml
mixed steroids were injected inside the orbit. After
the injections, ocular massage was performed and
intraocular pressure and vision were checked five
minutes later; the patients were discharged if the
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injection was found to be uneventful. In all patients,
the injections were repeated at least thrice at one
month intervals. If residual inflammatory signs were
present, a fourth injection was also added at the
same interval. All examinations were repeated the
day after the injection, and one and three months
after the last injection; any complications were
documented.
Changes in the disease severity and activity
were evaluated separately. For disease severity,
any improvement from higher to lower categories
of NOSPECS was defined as success. For disease
activity, a decrease in CAS to 3 or less was defined
as success. For proptosis, a decrease in exophthal-
mos of at least 2 mm; for lid retraction, a decrease
of at least 1 mm; and in case of ocular motility,
any improvement in duction limitations was defined
as success. If the disease became quiet and
stable at least three months after the last injection,
reconstructive or cosmetic procedures including
orbital decompression, strabismus surgery or lid
surgery were performed as required.
Data analysis was performed using SPSS soft-
ware version 25. For the description of findings,
we used percentage, mean, standard deviation,
mode, and range. For the comparison of study
parameters, we employed the paired T-test for
intragroup analysis; to compensate for the use
of fellow eyes from the same subject, we used
Generalized Estimating Equation (GEE) analysis.
Spearman correlation was used to evaluate the
relation between parameters.
P-values < 0.05 and confidence intervals of 95%
were used to determine the statistical significance.
RESULTS
Initially, 41 eyes of 22 patients were enrolled in
the study; however, five patients were excluded
from the final analysis due to non-adherence to
the treatment protocol. The results reported herein
are based on the data from 31 eyes of 17 patients.
Patient characteristics are detailed in Table 1. Mean
LogMAR visual acuity before the injections was 0.14
± 0.1, which remained stable at 0.13± 0.09 LogMAR
with no significant change (P = 0.3).
Before the injections, three eyes (9.7%) had
stage 5 disease according to the NOSPECS sever-
ity classification that improved to stage 4; in the
remaining cases, the disease severity remained
unchanged (P = 0.9). The mean CAS before the
intraorbital injections was 5.2 ± 1.3 that improved
to 2.7 ± 1 after the first injection and to 1.6 ± 1
at the final examination. Changes in CAS scores
were significant after every single injection (P <
0.001, P < 0.001, and P < 0.005 for the first to
third injections, respectively), but not significant
afterward. The most significant change in the
CAS score was observed after the first injection
[Figure 1].
Upper lid retraction was present in 17 eyes
(54.8%), which was improved by at least 1 mm or
more in all eyes (100%) at the final examination.
Lower lid retraction was present in 22 eyes (71%),
which was improved by 1 mm or more in 68.2%
of affected eyes at the final examination. The
mean amount of upper lid retraction before the
injections was 2.2 ± 1.3 (range, 1–4) mm, which
was reduced to 0.6 ± 1.1 (range, 0–3) (P < 0.001) at
the final examination. The mean amount of lower
lid retraction before the injections was 3.7 ± 1.9
(range, 1–9) mm, which was reduced to 2.5 ± 1.5
(range, 0–5) mm (P < 0.001) at the final follow-up.
The amount of improvement was significant only
after the first injection for upper lid retraction (P <
0.001) and after the first and second injections for
the lower lid retraction (P < 0.001 in both cases)
[Figure 2].
Five patents (29.4%) had strabismus prior to the
injections that included two cases of esotropia,
two cases of esotropia with hypotropia, and one
case of consecutive exotropia in a subject with a
history of twice weakening of bothmedial recti. The
mean amount of deviation before the injections
was 39.4 ± 29.8 Δ horizontal deviation (range 90
Δ ET to 15 Δ XT) with 54 ± 50.9 Δ (range, 18–90 Δ)
hypotropia, which remained unchanged at 38.8 ±
30.4 Δ horizontal deviation (range, 90 Δ ET to 12 Δ
XT) with 54 ± 50.9 Δ (range, 18–90 Δ) hypotropia
(P = 0.4 and P = 1, respectively).
The mean amount of limitation in supraduction
was –0.4 ± 1 (range, –4 to 0) before the injections,
which was improved to –0.2 ± 0.9 (range, –4 to
0) at the last follow-up (P = 0.04). The limitation in
abduction was –2.2 ± 0.8 (range, –4 to –1) before
the injections, which remained unchanged at –
2:00 ± 0.8 (range, –4 to –1) at the final follow-up (P
= 0.2). Changes in adduction and infraduction were
also not significant (P = 0.9 for both comparisons).
Exophthalmos was improved by at least 2 mm
in 7 eyes (22.6%), and by 1 mm or more in 17
eyes (54.8%) at the final follow-up. The Mean
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Table 1. Clinical and paraclinical characteristics of patients
Variables
Age Mean (range) 49.8 ± 12.2 (28–72 years)
Duration of Graves’ disease Mean (range) 7.3 ± 7.2 (9 months to 23 years)
Numbers (%)
Sex Male 11 (64.7%)
Female 6 (35.3%)
Smoking Smoker 9 (52.9%)
Nonsmoker 8 (47.1%)
Thyroid function when Graves’ ophthalmopathy started Hyperthyroid 16 (94.1%)
Hypothyroid 1 (5.9%)
History of surgeries for Graves’ ophthalmopathy Orbital decompression 4 (23.5%)
Strabismus surgery 2 (11.8%)
Eyelid surgery 2 (11.8%)




Present treatments for Graves’ disease Antithyroid (Methymazole) 11
Levothyroxine 3
Causes of using orbital steroid injections* Resistance to systemic steroids 5 (%29.4)
Dependence on systemic steroids 2 (%11.8)
Complications of systemic steroids 10 (%58.8)
Hypertension 7 (%41.2)
Hyperglycemia 3 (%17.6)
Moon face 2 (%11.8)
Major depression 1 (%5.9)
Flushing 1 (%5.9)
Severe weight gain 1 (%5.9)










*Some cases had more than one cause
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Figure 1. Bar diagram of changes in mean clinical activity score (CAS) before the injections up to the final examination.
Figure 2. Line diagram of changes in mean lids retraction before the injections up to the last examination.
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Figure 3. Bar diagram of changes in mean amount of proptosis before the injections up to the final examination.
exophthalmometry readings before the injections
was 22.4 ± 3.5 (range, 16–28) mm, which was
reduced to 21 ± 3.7 (range, 15–27) mm at the last
follow-up. The mean decrease in exophthalmos
was 1.2 ± 1.1 mm at the final follow-up as compared
to baseline values. The decrease in exophthalmos
was significant only after the first and second
injections (P < 0.001 and P = 0.05, respectively)
[Figure 3].
None of the changes observed in the study
parameters including disease severity according
to NOSPECS, disease activity according to CAS,
lid retraction, strabismus, ocular movements, and
exophthalmos had a significant correlation with
age, sex, length of thyroid ophthalmopathy, and
smoking [Figure 4].
After the injections, thyroid eye disease became
inactive in all eyes; thereafter operations were
performed in a number of cases including cosmetic
orbital decompression in seven eyes (22.6%), stra-
bismus surgery in four patients (23.5%), and eyelid
retraction surgery in three eyes (9.7%).
Overall intraocular pressure elevation occurred
after the injections in 10 out of 113 injections
(8.8%), ranging from 21 to 32 mmHg and was
controlled with topical medications after a few
days. In a total of 8 out of 113 (7.1%) injections, sub-
conjunctival hemorrhage or periorbital hematoma
occurred, which resolved spontaneously after a
few days. Other transient complications included
ptosis in one case, hyperpigmentation over the
injection sites in one case, and hypermenorrhea
in another case, all of which improved sponta-
neously.
DISCUSSION
The current study demonstrated that intraorbital
steroid injections can be used to control inflamma-
tion and decrease disease activity in Graves’ oph-
thalmopathy. These injections improve limitations
in ocular motility, exophthalmos and lid retraction,
and reduce the severity of the condition.
Oral or intravenous systemic steroids
are the drugs of choices for active Graves’
ophthalmopathy.[6, 7, 25] When the condition
does not respond to these routes of steroid
administration, or if the patient becomes
dependent on them or develops steroid-
related complications such as systemic
hypertension, hyperglycemia, gastric ulcer and
obesity, alternative modalities of treatments
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A B
C D
Figure 4. Two representative patients before injections (A,C) and at final examinations (B,D).
may be employed. These include orbital
radiotherapy,[26–28] cytotoxic drugs[29–31] or biologic
agents,[32] each of which entails shortcomings and
potential complications.[26–32]
Local injection of steroids has been performed
using a variety of methods for the treatment of
Graves’ ophthalmopathy. It has been used as sub-
conjunctival injections to treat lid retractions,[9–12]
which not only led to improved vision but also
decreased extraocular muscle thickness.[9] Our
treatment protocol that included retroseptal injec-
tions in both the superior and inferior orbital
spaces significantly improved upper and lower lid
retraction.
Authors using intraorbital steroid injections have
reported different results. Khafagy[16] reported
reduced proptosis in 80% and improvement in
ocular movements in 100% of their cases, while
Kim and Jung[15] concluded that orbital steroid
injections had no effect on proptosis or ocular
movements. In the current study, we observed a
mean improvement of 1.2 mm in proptosis and also
some improvement in ocular motility, especially in
supraduction, although the angle of strabismus did
not change significantly.
One of the most important parameters used for
evaluating the efficacy of local steroid injections
is the improvement in inflammatory signs. Bord-
aberry et al[17] reported a reduction of CAS from
6.4 to 1.8 with this treatment modality and even
improvement in compressive optic neuropathy in
66% of affected cases. Yakopson et al[18] showed
a decreased inflammation in 63% of their cases
while Jung and Kim[15] also reported a significant
improvement in inflammation. In our study, CAS
score decreased from 5.2 to 1.6, which indicates a
significant reduction in inflammation.
Various injection intervals have been
employed by different authors that include one
week,[13, 14, 16, 20] two weeks,[15, 17] three weeks,[12]
four weeks[9, 11] and even longer intervals of
about four months.[10, 18] We used four week
intervals because the effect of triamcinolone
lasts for four weeks,[19] so this interval seems
the most logical choice. Previous studies have
reported a total number of injections ranging
from one to twelve;[9–20] we observed that the
earliest injections are the most effective and
the therapeutic effect decreases with repeating
injections. In our patients, the decrease in CAS
score was significant up to three injections, but
not significant afterward. The effect on proptosis,
lid retraction, and extraocular muscles were also
significant up to two injections.
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Most authors have performed intraorbital injec-
tions via the inferotemporal area of the lower
lid.[13–16, 19, 20] Similar to our study, Bordaberry
et al[17] gave intraorbital injections via both lids
(superoanasal and inferotemporal) and reported
the greatest decrease in CAS scores. It seems
that injections at two sites through both eyelids
allow better distribution of the medications in the
orbit and provide a better therapeutic response.
Injections from two different sites within the orbit
may increase the risk of intraorbital pressure rise
and may also increase the risk of retroseptal
hemorrhage. Because of these considerations, we
did not include patients with compressive optic
neuropathy in our study, but it is interesting that
some studies have demonstrated benefits from
such therapy even in cases of compressive optic
neuropathy.[17, 33]
The most important complication reported after
intraorbital steroid injections is intraocular pres-
sure elevation. Even though certain studies have
not reported this complication,[14, 18] in others,
the pressure elevation was controlled with top-
ical medications,[16] but in one study this com-
plication was seen in 30% of the cases and
they had to control it in some cases by glau-
coma surgery.[13] In the present study, IOP rise
occurred after 8.8% of the injections and all
instances were readily controlled with topical
medications. Another complication in our cases
was subconjunctival or eyelid hematoma in 7.1%
of treated eyes which improved spontaneously.
A number of other complications have been
reported with this modality of treatment, such
as subcutaneous fat atrophy, globe perforation,
central retinal artery occlusion, and toxic optic
neuropathy.[14] Fortunately, such catastrophic com-
plications are rare and were not observed in our
study.
At the end of the study and after resolution
of disease activity, some patients required surgi-
cal intervention, which included cosmetic orbital
decompression in 22.6% of eyes, repair of lid
retraction in 9.7% of eyes, and strabismus surgery
in 23.5% of cases. In similar studies, a need
for orbital decompression was reported in 31.8–
55% of eyes, eyelid repair in 64% of eyes, and
strabismus surgery in 10.5–14%of cases,[13, 18]which
was roughly similar to our series.
The major drawback to our study is the lack of
a control group and the limited number of cases
because of the strict inclusion criteria. In the current
study, intraorbital injections were performed in the
operating room; if larger studies also demonstrate
the relative safety of the procedure, these injec-
tions may be used more liberally and with less
expense on an outpatient basis.
In summary, intraorbital steroid injections in
Graves’ ophthalmopathy can help decrease orbital
inflammation and are a good substitute to systemic
steroids when patients become steroid resistant
or dependent, or develop complications related to
them.
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